PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Viking Therapeutics, Inc. (VKTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US92686J1060

CUSIP

92686J106

Sector

Healthcare

IPO Date

Apr 29, 2015

Highlights

Market Cap

$5.79B

EPS (TTM)

-$0.94

PEG Ratio

-0.03

Total Revenue (TTM)

$436.00K

Gross Profit (TTM)

$126.00K

EBITDA (TTM)

-$133.82M

Year Range

$11.74 - $99.41

Target Price

$112.57

Short %

16.01%

Short Ratio

3.89

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
VKTX vs. SDGR VKTX vs. SNDX VKTX vs. MDGL VKTX vs. SCHD VKTX vs. IVV VKTX vs. NVDA VKTX vs. LLY VKTX vs. AMD VKTX vs. SMH VKTX vs. SPY
Popular comparisons:
VKTX vs. SDGR VKTX vs. SNDX VKTX vs. MDGL VKTX vs. SCHD VKTX vs. IVV VKTX vs. NVDA VKTX vs. LLY VKTX vs. AMD VKTX vs. SMH VKTX vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Viking Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%JulyAugustSeptemberOctoberNovemberDecember
-10.62%
14.33%
VKTX (Viking Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Viking Therapeutics, Inc. had a return of 170.07% year-to-date (YTD) and 233.29% in the last 12 months.


VKTX

YTD

170.07%

1M

-31.04%

6M

-10.62%

1Y

233.29%

5Y (annualized)

48.71%

10Y (annualized)

N/A

^GSPC (Benchmark)

YTD

26.84%

1M

5.60%

6M

14.34%

1Y

32.39%

5Y (annualized)

14.23%

10Y (annualized)

11.32%

Monthly Returns

The table below presents the monthly returns of VKTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202429.72%219.18%6.42%-2.95%-21.76%-14.86%7.53%12.49%-1.26%14.58%-27.02%170.07%
2023-6.81%25.68%51.23%27.99%3.05%-26.18%-10.55%-4.76%-19.84%-11.38%24.57%52.29%97.98%
2022-19.35%-9.70%-10.45%-20.67%-6.72%30.18%4.15%5.65%-14.47%50.74%-1.22%132.10%104.35%
202129.84%-7.80%-6.16%1.03%-18.00%14.31%2.67%7.48%-4.99%-7.32%-8.76%-13.37%-18.29%
2020-21.70%-5.73%-20.95%23.08%24.13%0.84%-2.64%-4.70%-13.00%-3.26%14.21%-12.44%-29.80%
20196.67%3.06%18.19%-21.23%-1.79%7.93%-7.35%-9.62%-1.01%-5.96%13.14%9.56%4.84%
201830.79%17.89%-30.19%-5.72%142.48%-5.01%7.48%28.14%33.28%-21.93%-16.99%-32.24%88.42%
201718.49%8.51%-4.58%-4.11%-15.71%-8.47%-2.78%-0.95%83.65%24.61%27.73%33.55%241.18%
2016-39.00%-12.98%-21.55%2.11%-4.83%-8.70%11.11%-4.29%4.56%-23.63%0.93%10.19%-65.10%
2015-1.79%-6.48%-13.24%-14.71%0.99%-4.72%-3.75%-43.26%6.56%-61.94%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of VKTX is 93, placing it in the top 7% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of VKTX is 9393
Overall Rank
The Sharpe Ratio Rank of VKTX is 8989
Sharpe Ratio Rank
The Sortino Ratio Rank of VKTX is 9696
Sortino Ratio Rank
The Omega Ratio Rank of VKTX is 9494
Omega Ratio Rank
The Calmar Ratio Rank of VKTX is 9898
Calmar Ratio Rank
The Martin Ratio Rank of VKTX is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for VKTX, currently valued at 1.90, compared to the broader market-4.00-2.000.002.004.001.902.59
The chart of Sortino ratio for VKTX, currently valued at 3.90, compared to the broader market-4.00-2.000.002.004.003.903.45
The chart of Omega ratio for VKTX, currently valued at 1.49, compared to the broader market0.501.001.502.001.491.48
The chart of Calmar ratio for VKTX, currently valued at 5.74, compared to the broader market0.002.004.006.005.743.73
The chart of Martin ratio for VKTX, currently valued at 9.51, compared to the broader market0.0010.0020.0030.009.5116.58
VKTX
^GSPC

The current Viking Therapeutics, Inc. Sharpe ratio is 1.90. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Viking Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.002.003.004.005.00JulyAugustSeptemberOctoberNovemberDecember
1.90
2.59
VKTX (Viking Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Viking Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-46.81%
0
VKTX (Viking Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Viking Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Viking Therapeutics, Inc. was 90.41%, occurring on Aug 2, 2017. Recovery took 208 trading sessions.

The current Viking Therapeutics, Inc. drawdown is 46.81%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-90.41%May 7, 2015565Aug 2, 2017208May 31, 2018773
-89.26%Sep 20, 2018942Jun 16, 2022209Apr 18, 20231151
-62.73%Jun 9, 202398Oct 27, 202370Feb 8, 2024168
-49.85%Feb 29, 202482Jun 26, 2024
-25.51%Jun 18, 201810Jun 29, 201843Aug 30, 201853

Volatility

Volatility Chart

The current Viking Therapeutics, Inc. volatility is 22.34%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%JulyAugustSeptemberOctoberNovemberDecember
22.34%
3.39%
VKTX (Viking Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Viking Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Viking Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab